LAURUSLABS - Laurus Labs Limited Share Price

Pharmaceuticals & Biotechnology

₹626.50+0.85(+0.14%)

Market Closed as of Apr 28, 2025, 15:30 IST

What does Laurus Labs Limited do?

Pharmaceuticals•Healthcare•Small Cap

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:6,007

Website:www.lauruslabs.com

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	LAURUSLABS	Pharmaceuticals
PE	168.20	37.19
PS	6.36	5.23
Growth	6.3 %	7.1 %

Summary of Latest Earnings Report from Laurus Labs

Summary of Laurus Labs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Jan 25

Management Outlook: Laurus Labs anticipates strong growth driven by robust CDMO performance, with FY25 EBITDA margins expected around 20% and gradual deleveraging. The CDMO division is projected to accelerate, supported by late-stage project deliveries in Q4 and a growing pipeline (90+ active projects). The company remains confident in long-term value creation, particularly in complex small molecules, fermentation, and biotech (via Eight Roads partnership). ARV revenues (APIs + formulations) are expected to stabilize at ~INR650 crore/quarter, while formulations and non-ARV APIs are set to recover with ANDA launches and KrKa collaboration.

Key Highlights:

CDMO Growth: Achieved record quarterly revenue (~INR400 crore), driven by human/animal health projects. Focus on high-value APIs (not intermediates) and advanced technologies (flow chemistry, biocatalysis).
Financial Health: Q3 revenue up 18% YoY to INR1,415 crore; EBITDA margin improved to 20.1%. Gross margins remained strong (~57%) due to product mix.
Expansions: Bio division to double fermentation capacity by 2026 with Eight Roads' investment. Gene therapy (viral vectors) facility (INR120"“130 crore capex) targeted for FY26.
ARV Stabilization: API sales declined 7% (prioritizing high-margin products), but order book remains healthy. ARV formulations grew to INR304 crore in Q3.
R&D Focus: Filed 4 DMFs (3 non-ARV) in 9M FY25; 43 ANDAs filed (21 approved). Validating products under KrKa's CMO agreement.
Debt: Net debt at INR2,766 crore; expects deleveraging as operations scale.
Quality Compliance: Passed 120+ audits without critical findings.

Q&A Session

Last updated: Jan 25

Question 1:
"First question is related to Laurus Bio. Recently, a 59-year-old female patient from Netherlands travelled to India for CAR-T cell therapy... Can these individually become multitherapy assets at scale?"
Answer:
ImmunoACT (Laurus' associate) expanded beyond a single product, initiating trials for BCMA CAR-T therapy and advancing other assets. The gene therapy collaboration with IIT Kanpur is progressing, with updates expected later.

Question 2:
"Given our reactors are interchangeable... we would rather do a 70% gross margin molecule. Is that how you would think as well?"
Answer:
ARV remains a stable "cash cow" business, but Laurus can repurpose capacity for higher-margin products if external conditions (e.g., PEPFAR tenders) shift, as demonstrated by past adjustments (e.g., efavirenz volume reduction).

Question 3:
"How much of the ARV formulation sales for the quarter?"
Answer:
ARV formulation sales in Q3 FY25 were Rs.304 crores.

Question 4:
"Regarding the investment by Eight Roads... Is this 400KL capacity another project?"
Answer:
The 400KL fermentation facility in Vizag (operational by 2026) and Mysore are part of Laurus Bio's expansion. Eight Roads' investment supports technical collaboration, not direct capacity creation.

Question 5:
"Total ARV vs. non-ARV revenue for the quarter?"
Answer:
Total ARV revenue (API + formulations) was Rs.619 crores in Q3. Laurus expects annual ARV revenue to stabilize between Rs.2,300"“2,500 crores, with no significant growth ahead.

Question 6:
"When is the Bio plant going live? When will KrKa's FDF capacity contribute?"
Answer:
The Vizag Bio facility will operationalize by late 2026. KrKa's validation is underway, with revenue from Unit 2 expected from late 2025.

Question 7:
"Impact of the US Biosecure Act on supply chain diversification momentum?"
Answer:
No slowdown observed; RFPs and partner engagements remain robust.

Question 8:
"Can Q4 meet the H2 EBITDA margin target of 25%?"
Answer:
Laurus reaffirms FY25 EBITDA margin guidance of ~20%, citing improved product mix and operating leverage.

Question 9:
"Will FY26 see a CDMO revenue breakthrough (e.g., Rs.2,500 crores)?"
Answer:
CDMO growth is strong, with FY26 expected to outperform FY25, driven by late-stage projects and Animal Health/Crop Science commercialization.

Question 10:
"How many commercial molecules will CDMO commercialize in FY26?"
Answer:
Laurus avoided specifics but highlighted a diversified pipeline of 90+ projects, focusing on complex APIs and volume-driven growth.

Question 11:
"Shift from RSMs/intermediates to APIs: rationale and timeline?"
Answer:
Strategic realignment toward high-value APIs leverages Laurus' tech platforms (flow chemistry, biocatalysis). This shift is progressive, driven by customer demand and capability enhancement.

Question 12:
"What drove Q3 CDMO growth? Sustainability?"
Answer:
Growth came from human health (primary) and animal health CDMO, driven by late-stage project deliveries. Sustainability is supported by a robust pipeline and capacity utilization.

Question 13:
"Impact of US exiting WHO on ARV?"
Answer:
Minimal near-term impact expected, as WHO doesn't fund procurements. ARV purchases (~10% of HIV program budgets) are likely unaffected.

Question 14:
"Why was Richcore's fermentation facility moved to Mysore?"
Answer:
Geographic adjustments (Vizag prioritized for operational efficiency) align with long-term plans for two large-scale Bio facilities (Vizag and Mysore).

Question 15:
"Valuation rationale for Eight Roads' Laurus Bio investment?"
Answer:
Partnership aims to leverage Eight Roads' portfolio for business growth, not mere capital. Laurus and Eight Roads invested at "fair" valuations, with Laurus committing additional Rs.40 crores.

Question 16:
"Oncology API decline in Q3?"
Answer:
Temporary order timing issues; Laurus maintains strong market share in key APIs (e.g., gemcitabine) with a healthy pipeline.

Question 17:
"Registration batches in Q3/Q4: single or multiple products?"
Answer:
Multiple products supplied in Q3, with more slated for Q4.

Question 18:
"CDMO's "˜breakthrough designated molecules' significance?"
Answer:
Accelerates partner approvals but Laurus avoids therapeutic area disclosures due to confidentiality.

Question 19:
"Capex reduction plans?"
Answer:
Capex remains opportunistic, prioritizing high-value segments (CDMO, Bio). FY25 capex: Rs.448 crores (9M), with FY26 investments tied to project demand.

Question 20:
"R&D hiring challenges amid Hyderabad's GCC growth?"
Answer:
Laurus emphasizes culture, employee ownership (stock options), and family-centric programs to attract/retain talent, mitigating regional competition.

Share Holdings

Understand Laurus Labs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava)	23.02%
NEW WORLD FUND INC	6.5%
ANUKAR PROJECTS PRIVATE LIMITED	3.24%
CHUNDURU VENKATA LAKSHMANA RAO	2.65%
SBI ARBITRAGE OPPORTUNITIES FUND	1.82%
AKASH BHANSHALI	1.33%
M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram)	1.24%
DSP ARBITRAGE FUND	1.16%
KOTAK FUNDS - INDIA MIDCAP FUND	1.16%
BARCLAYS WEALTH TRUSTEES INDIA PRIVATE LIMITED	1.14%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	1.02%
SATYANARAYANA CHAVA	0.29%
VENKATA RAVI KUMAR VANTARAM	0.19%
KRISHNAVENI VASIREDDI	0.04%
HYMAVATHI VANTARAM	0.04%
NARASIMHA RAO SURYADEVARA	0.03%
RAMA SURYADEVARA	0.03%
SEKHAR BABU CHUNDURU	0.02%
KAMALA KOMMANA	0.02%
NAGAMANI THOKALA	0.02%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Cash Flow for Laurus Labs

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-75.2%	-20.37	-11.2	-8.07
Change in inventories	-209.2%	-127.87	119	-155.18
Depreciation	14.7%	345	301	235
Unrealised forex losses/gains	-143.2%	-6.77	19	7.34
Share-based payments	54.3%	11	7.48	6.64
Net Cashflows from Operations	-40.5%	608	1,022	909
Interest paid	-13.3%	-143.81	-126.84	-80.3
Income taxes paid (refund)	-63.7%	98	268	166
Other inflows (outflows) of cash	4800%	4.92	1.08	0
Net Cashflows From Operating Activities	-25.3%	659	882	823
Cashflows used in obtaining control of subsidiaries	1090.5%	251	22	43
Proceeds from sales of PPE	139.1%	1.55	1.23	0.06
Purchase of property, plant and equipment	-50.6%	367	742	761
Cash receipts from repayment of advances and loans made to other parties	84.6%	121	66	0
Interest received	133.3%	22	10	12
Other inflows (outflows) of cash	4.8%	0	-0.05	-0.23
Net Cashflows From Investing Activities	-2.9%	-756.74	-735.27	-836.61
Proceeds from exercise of stock options	-75.8%	2.56	7.44	4.31
Proceeds from borrowings	105.2%	553	270	377
Repayments of borrowings	-20.9%	179	226	155
Payments of lease liabilities	33.8%	7.41	5.79	45
Dividends paid	-19.8%	86	107	86
Interest paid	16.4%	143	123	80
Net Cashflows from Financing Activities	174.1%	139	-185.19	15
Net change in cash and cash eq.	200.2%	41	-38.91	1.55

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Change in inventories	-288%	-151.31	82	-174.33
Depreciation	18.9%	385	324	251
Unrealised forex losses/gains	-189.3%	-8.82	12	0
Adjustments for interest income	29.5%	5.61	4.56	1.72
Share-based payments	54.3%	11	7.48	6.64
Net Cashflows from Operations	-47.9%	590	1,132	1,007
Interest paid	-20.2%	-175	-145.47	-86.19
Income taxes paid (refund)	-63.4%	105	285	182
Other inflows (outflows) of cash	504.6%	4.93	1.65	0
Net Cashflows From Operating Activities	-33%	666	994	911
Cashflows used in obtaining control of subsidiaries	276.2%	80	22	0
Proceeds from sales of PPE	-22.2%	2.3	2.67	0.12
Purchase of property, plant and equipment	-31.5%	678	990	877
Interest received	29.5%	5.61	4.56	1.72
Other inflows (outflows) of cash	-117.1%	-0.4	9.17	-11.74
Net Cashflows From Investing Activities	17.4%	-822.42	-996.06	-914.34
Proceeds from exercise of stock options	-75.8%	2.56	7.44	4.31
Proceeds from borrowings	62.1%	758	468	438
Repayments of borrowings	-12.2%	217	247	168
Payments of lease liabilities	368.5%	33	7.83	73
Dividends paid	-19.8%	86	107	86
Interest paid	24.5%	174	140	85
Net Cashflows from Financing Activities	1000.9%	250	-26.64	30
Effect of exchange rate on cash eq.	55.9%	0.17	-0.88	-0.13
Net change in cash and cash eq.	399.9%	93	-29.68	27

Income Statement for Laurus Labs

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	6.8%	1,265	1,185	1,117	1,415	1,132	1,158
Other Income	-44.4%	7.12	12	9.3	24	11	5.9
Total Income	6.3%	1,272	1,197	1,126	1,439	1,143	1,164
Cost of Materials	8.3%	629	581	557	580	628	658
Purchases of stock-in-trade	36%	35	26	23	41	18	26
Employee Expense	8.8%	162	149	149	138	134	143
Finance costs	6.8%	48	45	41	42	38	38
Depreciation and Amortization	-2.2%	89	91	91	89	87	85
Other expenses	1%	296	293	286	289	292	271
Total Expenses	5%	1,196	1,139	1,087	1,274	1,086	1,101
Profit Before exceptional items and Tax	33.3%	77	58	39	164	57	63
Total profit before tax	33.3%	77	58	39	164	57	63
Current tax	52.4%	33	22	17	46	17	18
Deferred tax	-92.5%	-13.09	-6.32	-7.24	-2.95	-3.21	-1.76
Total tax	20%	19	16	10	43	14	17
Total profit (loss) for period	36.6%	57	42	29	121	43	47
Other comp. income net of taxes	-1.4%	0.28	0.29	0.28	2.91	-1.22	-1.23
Total Comprehensive Income	35.7%	58	43	29	124	41	45
Earnings Per Share, Basic	128.6%	1.06	0.79	0.53	2.25	0.79	0.87
Earnings Per Share, Diluted	128.6%	1.06	0.79	0.53	2.25	0.79	0.87

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-16.6%	4,812	5,773	4,707	4,769	2,797	2,236
Other Income	206.7%	47	16	22	27	5.81	16
Total Income	-16.1%	4,860	5,789	4,729	4,796	2,803	2,252
Cost of Materials	-4.7%	2,397	2,516	2,281	2,375	1,605	1,215
Purchases of stock-in-trade	-29%	111	156	146	96	16	22
Employee Expense	11.1%	552	497	445	402	324	270
Finance costs	3.4%	151	146	96	66	88	86
Depreciation and Amortization	14.7%	345	301	235	197	184	161
Other expenses	2%	1,105	1,083	768	682	501	406
Total Expenses	-3.8%	4,558	4,738	3,753	3,521	2,499	2,131
Profit Before exceptional items and Tax	-71.4%	301	1,051	975	1,275	304	121
Total profit before tax	-71.4%	301	1,051	975	1,275	304	121
Current tax	-67.8%	88	271	231	335	53	25
Deferred tax	-158.8%	-10.17	20	-6.1	-16.46	-15.57	1.39
Total tax	-73.4%	78	291	225	319	37	26
Total profit (loss) for period	-70.6%	224	760	750	956	267	95
Other comp. income net of taxes	-738.1%	-0.76	0.79	0.8	5.12	-9.62	-3.07
Total Comprehensive Income	-70.8%	223	761	751	961	257	92
Earnings Per Share, Basic	-76%	4.15	14.14	13.97	17.85	56	1.788
Earnings Per Share, Diluted	-75.9%	4.15	14.09	13.91	17.77	56	1.784

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	15.6%	1,415	1,224	1,195	1,440	1,195	1,224
Other Income	133.9%	9.42	4.6	2.51	19	2.43	1.78
Total Income	16%	1,424	1,228	1,197	1,458	1,197	1,226
Cost of Materials	13.2%	653	577	572	591	634	673
Purchases of stock-in-trade	36%	35	26	23	41	18	26
Employee Expense	5.6%	189	179	174	161	155	164
Finance costs	9.6%	58	53	49	50	51	42
Depreciation and Amortization	-1.9%	106	108	106	102	98	93
Other expenses	4.1%	331	318	313	315	313	292
Total Expenses	7.4%	1,294	1,205	1,179	1,351	1,163	1,172
Profit Before exceptional items and Tax	490.9%	131	23	18	107	35	54
Total profit before tax	490.9%	131	23	18	107	35	54
Current tax	54.5%	35	23	18	43	18	15
Deferred tax	121.5%	5.1	-18.09	-12.16	-11.4	-8.95	-0.74
Total tax	853.5%	40	5.09	6.25	32	9.45	15
Total profit (loss) for period	384.2%	93	20	13	75	23	37
Other comp. income net of taxes	-73.9%	-1.47	-0.42	0.31	2.26	-1.05	-1.65
Total Comprehensive Income	373.7%	91	20	13	77	22	35
Earnings Per Share, Basic	212.7%	1.71	0.37	0.23	1.4	0.43	0.69
Earnings Per Share, Diluted	212.7%	1.71	0.37	0.23	1.4	0.43	0.68

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-16.6%	5,041	6,041	4,936	4,814	2,832	2,292
Other Income	400%	26	6	15	24	5.92	16
Total Income	-16.2%	5,067	6,047	4,951	4,837	2,838	2,308
Cost of Materials	-6.7%	2,422	2,597	2,269	2,359	1,614	1,245
Purchases of stock-in-trade	-29%	111	156	146	96	16	22
Employee Expense	10.2%	640	581	502	434	345	289
Finance costs	11%	183	165	102	68	90	88
Depreciation and Amortization	18.9%	385	324	251	205	187	164
Other expenses	9%	1,191	1,093	818	671	509	411
Total Expenses	-2.2%	4,831	4,938	3,867	3,536	2,544	2,188
Profit Before exceptional items and Tax	-78.8%	236	1,109	1,084	1,301	294	120
Total profit before tax	-78.8%	236	1,109	1,084	1,301	294	120
Current tax	-68.2%	93	290	254	338	54	25
Deferred tax	-223.6%	-24.96	22	-2.8	-20.31	-15.24	1.16
Total tax	-78.5%	68	312	251	317	38	26
Total profit (loss) for period	-79.7%	162	793	832	984	255	94
Other comp. income net of taxes	41.6%	-2.87	-5.63	1.03	5.01	-11.38	-3.67
Total Comprehensive Income	-79.9%	159	788	833	989	244	90
Earnings Per Share, Basic	-85.5%	2.98	14.69	15.42	18.36	4.786	1.766
Earnings Per Share, Diluted	-85.6%	2.97	14.64	15.35	18.28	4.786	1.76

Valuation
Market Cap	33.74 kCr
Price/Earnings (Trailing)	168.2
Price/Sales (Trailing)	6.36
EV/EBITDA	37.03
Price/Free Cashflow	-2.04 K
MarketCap/EBT	120.83

Fundamentals
Revenue (TTM)	5.31 kCr
Rev. Growth (Yr)	18.97%
Rev. Growth (Qtr)	15.97%
Earnings (TTM)	200.59 Cr
Earnings Growth (Yr)	298.2%
Earnings Growth (Qtr)	365.86%

Profitability
Operating Margin	5.26%
EBT Margin	5.26%
Return on Equity	4.84%
Return on Assets	2.3%
Free Cashflow Yield	-0.05%

Investor Care
Dividend Yield	0.13%
Dividend/Share (TTM)	0.8
Shares Dilution (1Y)	0.05%
Diluted EPS (TTM)	3.71

Financial Health
Current Ratio	1.19
Debt/Equity	0.66
Debt/Cashflow	0.24

Balance Sheet for Laurus Labs

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-76.2%	11	43	30	1.42	1.82	40
Loans, current	0.9%	6.65	6.6	6.5	6.59	97	89
Total current financial assets	5.9%	1,799	1,699	1,525	1,512	1,637	1,400
Inventories	13.4%	1,924	1,697	1,734	1,569	2,140	1,689
Total current assets	9.9%	3,865	3,517	3,382	3,171	3,879	3,205
Property, plant and equipment	-4.3%	2,779	2,903	2,897	2,781	2,619	2,082
Capital work-in-progress	63.9%	255	156	231	357	422	755
Investment property	-3.5%	112	116	93	91	91	-
Non-current investments	0%	635	635	432	384	362	362
Loans, non-current	40.9%	318	226	191	64	0	0
Total non-current financial assets	10.2%	997	905	668	495	410	408
Total non-current assets	1.8%	4,224	4,150	3,939	3,787	3,615	3,404
Total assets	5.5%	8,088	7,667	7,322	6,958	7,495	6,609
Borrowings, non-current	-20%	393	491	453	565	470	550
Total non-current financial liabilities	-18.4%	444	544	484	594	498	579
Provisions, non-current	4.6%	92	88	89	79	78	70
Total non-current liabilities	1.1%	733	725	680	795	729	786
Borrowings, current	21.2%	1,890	1,559	1,319	1,116	1,423	1,070
Total current financial liabilities	14.7%	2,985	2,602	2,329	1,931	2,781	2,211
Provisions, current	8.7%	26	24	22	19	17	16
Current tax liabilities	-3%	33	34	17	44	96	28
Total current liabilities	12.8%	3,085	2,736	2,588	2,106	2,979	2,434
Total liabilities	10.3%	3,818	3,460	3,269	2,901	3,708	3,220
Equity share capital	0%	108	108	108	108	107	107
Total equity	1.5%	4,270	4,207	4,053	4,057	3,786	3,388
Total equity and liabilities	5.5%	8,088	7,667	7,322	6,958	7,495	6,609

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-69.6%	43	139	67	46	50	75
Loans, current	-300%	0.8	0.95	0.89	0.97	0.89	0.64
Total current financial assets	-0.6%	1,803	1,814	1,632	1,646	1,790	1,433
Inventories	14.2%	2,107	1,845	1,866	1,685	2,261	1,760
Total current assets	7.4%	4,120	3,835	3,668	3,462	4,173	3,345
Property, plant and equipment	-1.3%	3,401	3,446	3,315	3,016	2,835	2,257
Capital work-in-progress	23.2%	521	423	444	551	471	813
Investment property	-4%	171	178	156	133	134	138
Goodwill	0%	246	246	246	246	246	246
Non-current investments	2.4%	127	124	94	50	30	31
Total non-current financial assets	2.9%	176	171	143	99	93	91
Total non-current assets	1.3%	4,610	4,552	4,390	4,199	3,883	3,623
Total assets	4.1%	8,729	8,387	8,058	7,660	8,056	6,968
Borrowings, non-current	-17.2%	661	798	653	761	540	596
Total non-current financial liabilities	-15.5%	763	903	784	890	661	719
Provisions, non-current	5.4%	98	93	93	81	81	73
Total non-current liabilities	-2.8%	1,126	1,159	1,069	1,179	943	928
Borrowings, current	20.6%	2,060	1,709	1,435	1,211	1,512	1,136
Total current financial liabilities	12.9%	3,283	2,907	2,587	2,119	2,934	2,318
Provisions, current	8.3%	27	25	22	20	18	16
Current tax liabilities	5.7%	38	36	24	65	113	38
Total current liabilities	11.2%	3,459	3,112	2,945	2,432	3,340	2,681
Total liabilities	7.4%	4,585	4,271	4,015	3,612	4,283	3,609
Equity share capital	0%	108	108	108	108	107	107
Non controlling interest	148.6%	10	4.62	13	11	9.39	7.86
Total equity	0.7%	4,144	4,116	4,043	4,049	3,773	3,359
Total equity and liabilities	4.1%	8,729	8,387	8,058	7,660	8,056	6,968

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.42 LCr	53.56 kCr	+6.16%	+22.24%	38.52	8.25	+10.28%	+28.38%
DIVISLAB	Divi's LabPharmaceuticals	1.6 LCr	9.42 kCr	+4.55%	+50.34%	77.55	17.01	+20.50%	+49.46%
CIPLA	CiplaPharmaceuticals	1.26 LCr	27.8 kCr	+7.81%	+10.34%	25.18	4.52	+7.01%	+33.22%
DRREDDY	Dr. Reddy's LabPharmaceuticals	1 LCr	32.07 kCr	+4.76%	-4.14%	18.36	3.12	+14.31%	+4.21%
AUROPHARMA	Aurobindo PharmaPharmaceuticals	72.44 kCr	31.57 kCr	+7.47%	+10.24%	20.77	2.29	+10.80%	+26.04%

LAURUSLABS - Laurus Labs Limited Share Price

What does Laurus Labs Limited do?

Sector Comparison: LAURUSLABS vs Pharmaceuticals & Biotechnology

Comparative Metrics

Performance Comparison

Summary of Latest Earnings Report from Laurus Labs

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Cash Flow for Laurus Labs

Income Statement for Laurus Labs

Valuation

Fundamentals

Profitability

Investor Care

Financial Health

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Balance Sheet for Laurus Labs

Is Laurus Labs Better than it's peers?